Japan · Delayed Price · Currency is JPY BrightPath Biotherapeutics Company Description
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan.
It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Phase I clinical trials to treat melanoma.
The company is also developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers.
In addition, its product candidates in preclinical trials include BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1200 to target CD73.
The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017.
BrightPath Biotherapeutics Co., Ltd. was incorporated in 2003 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Kenichi Nagai |
Contact Details
Address: Kojimachi Central Building Tokyo, Tokyo Tokyo Japan | |
| Website | brightpathbio.com |
Stock Details
| Ticker Symbol | 4594 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3274140007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kenichi Nagai | Chief Executive Officer |
| Yoichi Takeshita | Chief Financial Officer |